Rgenta Therapeutics Announces RGT-61159 Clinical Poster Presentation at the Upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Imperative Care Initiates ADAPT 2.0 Study Evaluating Advanced Clinical Technique Designed to Simplify Acute Ischemic Stroke Treatment
Zenas BioPharma Announces Pricing of Concurrent Public Offerings of 2.50% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $300.0 Million
Imperative Care Initiates CLEAR-IT Clinical Study to Address Critical Gaps in Clinical Standards for Peripheral Thromboembolism
Eccogene Announces First Patient Enrolled in MIST Phase 2a Trial Evaluating ECC4703 as an Adjunct to Semaglutide for the Treatment of Obesity
Rgenta Therapeutics Presents Preclinical Data, Unveiling its New Drug Candidate, RGT-0474060, as a Promising Oral PMS1 Inhibitor for the Treatment of Huntington’s Disease
Eccogene Announces Positive Topline Results from Phase 1b Trial of Elecoglipron (AZD5004/ECC5004), an Oral GLP-1 Receptor Agonist, in Adult Participants Living with Obesity/Overweight, with or without Type 2 Diabetes in China
